Cargando…

Role of telavancin in treatment of skin and skin structure infections

Skin and skin structure infections (SSSIs) are a common diagnosis encountered by ambulatory and inpatient practitioners across the country. As the SSSIs become more complicated, they require increased health care resources and often involve hospitalization and intravenous antimicrobials. Complicated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonkowski, Joseph, Daniels, Anne R, Peppard, William J
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047943/ https://www.ncbi.nlm.nih.gov/pubmed/21437067 http://dx.doi.org/10.2147/CCID.S9027

Ejemplares similares

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Moxifloxacin in the treatment of skin and skin structure infections
por: Guay, David RP
Publicado: (2006)

Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
por: Ferrández, Olivia, et al.
Publicado: (2016)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Skin and skin structure infections: treatment with newer generation fluoroquinolones
por: Giordano, Philip, et al.
Publicado: (2007)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections
por: Shoemaker, D Matthew, et al.
Publicado: (2006)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections
por: Townsend, Mary L, et al.
Publicado: (2007)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus
por: Peppard, William J, et al.
Publicado: (2009)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections
por: Hall, Ronald G, et al.
Publicado: (2015)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

Current Treatment Options for Acute Skin and Skin-structure Infections
por: Golan, Yoav
Publicado: (2019)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department
por: Almarzoky Abuhussain, Safa S., et al.
Publicado: (2018)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

New developments in the management of severe skin and deep skin structure infections – focus on tedizolid
por: Durkin, Michael J, et al.
Publicado: (2015)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
por: Bassetti, Matteo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ssm5f66l9a25430m2c51b73vv5